过氧化物酶体增殖物激活受体α的激活可保护心脏免受缺血/再灌注损伤。

Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury.

作者信息

Yue Tian-li, Bao Weike, Jucker Beat M, Gu Juan-li, Romanic Anne M, Brown Peter J, Cui Jianqi, Thudium Douglas T, Boyce Rogely, Burns-Kurtis Cynthia L, Mirabile Rosanna C, Aravindhan Karpagam, Ohlstein Eliot H

机构信息

GlaxoSmithKline Pharmaceuticals, King of Prussia, 709 Swedeland Rd, King of Prussia, Pa 19406, USA.

出版信息

Circulation. 2003 Nov 11;108(19):2393-9. doi: 10.1161/01.CIR.0000093187.42015.6C. Epub 2003 Oct 13.

Abstract

BACKGROUND

Peroxisome proliferator-activated receptor-alpha (PPAR-alpha) is expressed in the heart and regulates genes involved in myocardial fatty acid oxidation (FAO). The role of PPAR-alpha in acute ischemia/reperfusion myocardial injury remains unclear.

METHODS AND RESULTS

The coronary arteries of male mice were ligated for 30 minutes. After reperfusion for 24 hours, ischemic and infarct sizes were determined. A highly selective and potent PPAR-alpha agonist, GW7647, was administered by mouth for 2 days, and the third dose was given 1 hour before ischemia. GW7647 at 1 and 3 mg x kg(-1) x d(-1) reduced infarct size by 28% and 35%, respectively (P<0.01), and myocardial contractile dysfunction was also improved. Cardioprotection by GW7647 was completely abolished in PPAR-alpha-null mice. Ischemia/reperfusion downregulated mRNA expression of cardiac PPAR-alpha and FAO enzyme genes, decreased myocardial FAO enzyme activity and in vivo cardiac fat oxidation, and increased serum levels of free fatty acids. All of these changes were reversed by GW7647. Moreover, GW7647 attenuated ischemia/reperfusion-induced release of multiple proinflammatory cytokines and inhibited neutrophil accumulation and myocardial expression of matrix metalloproteinases-9 and -2. Furthermore, GW7647 inhibited nuclear factor-kappaB activation in the heart, accompanied by enhanced levels of inhibitor-kappaBalpha.

CONCLUSIONS

Activation of PPAR-alpha protected the heart from reperfusion injury. This cardioprotection might be mediated through metabolic and antiinflammatory mechanisms. This novel effect of the PPAR-alpha agonist could provide an added benefit to patients treated with PPAR-alpha activators for dyslipidemia.

摘要

背景

过氧化物酶体增殖物激活受体α(PPAR-α)在心脏中表达,并调节参与心肌脂肪酸氧化(FAO)的基因。PPAR-α在急性缺血/再灌注心肌损伤中的作用仍不清楚。

方法与结果

将雄性小鼠冠状动脉结扎30分钟。再灌注24小时后,测定缺血面积和梗死面积。一种高选择性和强效的PPAR-α激动剂GW7647经口给药2天,第三剂在缺血前1小时给予。1和3mg·kg⁻¹·d⁻¹的GW7647分别使梗死面积减少28%和35%(P<0.01),心肌收缩功能障碍也得到改善。GW7647的心脏保护作用在PPAR-α基因敲除小鼠中完全消失。缺血/再灌注下调心脏PPAR-α和FAO酶基因的mRNA表达,降低心肌FAO酶活性和体内心脏脂肪氧化,并增加血清游离脂肪酸水平。所有这些变化均被GW7647逆转。此外,GW7647减弱缺血/再灌注诱导的多种促炎细胞因子释放,抑制中性粒细胞聚集以及基质金属蛋白酶-9和-2的心肌表达。此外,GW7647抑制心脏中核因子-κB的激活,同时伴随抑制蛋白-κBα水平升高。

结论

PPAR-α的激活可保护心脏免受再灌注损伤。这种心脏保护作用可能通过代谢和抗炎机制介导。PPAR-α激动剂的这种新作用可能为接受PPAR-α激活剂治疗血脂异常的患者带来额外益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索